Xiao-yong P. Huang

Zhongshan, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 46 publications

FGFR2 Fusion-Driven CXCL3 Downregulation Attenuates Neutrophil Recruitment in Intrahepatic Cholangiocarcinoma.

FGFR2 Fusion-Driven CXCL3 Downregulation Attenuates Neutrophil Recruitment in Intrahepatic Cholangiocarcinoma.

Journal: Cancer letters

Published: March 05, 2026

Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma.

Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma.

Journal: The New England journal of medicine

Published: March 04, 2026

Anti-PD1 antibody toripalimab combined with lenvatinib, or GEMOX chemotherapy combined with lenvatinib as first-line therapy in patients with advanced intrahepatic cholangiocarcinoma: a randomized, open, two-cohort Phase 2 Study.

Anti-PD1 antibody toripalimab combined with lenvatinib, or GEMOX chemotherapy combined with lenvatinib as first-line therapy in patients with advanced intrahepatic cholangiocarcinoma: a randomized, open, two-cohort Phase 2 Study.

Journal: BMC medicine

Published: February 24, 2025

Lysine-specific demethylase 1 deletion reshapes tumour microenvironment to overcome acquired resistance to anti-programmed death 1 therapy in liver cancer.

Lysine-specific demethylase 1 deletion reshapes tumour microenvironment to overcome acquired resistance to anti-programmed death 1 therapy in liver cancer.

Journal: Clinical and translational medicine

Published: October 13, 2024

Application of a single-cell-RNA-based biological-inspired graph neural network in diagnosis of primary liver tumors.

Application of a single-cell-RNA-based biological-inspired graph neural network in diagnosis of primary liver tumors.

Journal: Journal of translational medicine

Published: April 14, 2024

Correction: Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis.

Correction: Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis.

Journal: Molecular cancer

Published: February 29, 2024

Construction of a prognostic model for hepatocellular carcinoma based on pyroptosis-related genes

Construction of a prognostic model for hepatocellular carcinoma based on pyroptosis-related genes

Journal: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

Published: June 26, 2023

Oncogenic miR-93-5p/Gal-9 axis drives CD8 (+) T-cell inactivation and is a therapeutic target for hepatocellular carcinoma immunotherapy.

Oncogenic miR-93-5p/Gal-9 axis drives CD8 (+) T-cell inactivation and is a therapeutic target for hepatocellular carcinoma immunotherapy.

Journal: Cancer letters

Published: January 05, 2023

Corrigendum to: "PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma" [J Hepatol 77 (2022) 163-176].

Corrigendum to: "PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma" [J Hepatol 77 (2022) 163-176].

Journal: Journal of hepatology

Published: December 23, 2022

The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion.

The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion.

Journal: Hepatology international

Published: August 17, 2022

Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study.

Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study.

Journal: Signal transduction and targeted therapy

Published: August 11, 2022

Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma.

Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma.

Journal: Nature communications

Published: August 08, 2022

Showing 1-12 of 46

Last Updated: 09/26/2026